X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-07-16 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale+OE | $52.95 | -10,000 | 91,488 | -10% | -$529,467 | |||||
2025-07-17 | IRON | Disc Medicine, Inc. | Franchi Jean M. | CFO | S - Sale | $59.00 | -2,031 | 63,499 | -3% | -$119,829 | ||||||
2025-07-16 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale | $9.29 | -1,296 | 92,450 | -1% | -$12,033 | ||||||
2025-07-16 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | CEO | S - Sale | $9.29 | -7,534 | 298,661 | -2% | -$69,953 | ||||||
| DM | 2025-07-16 | MDGL | Madrigal Pharmaceuticals, Inc. | Friedman Paul A | Dir | S - Sale+OE | $353.19 | -28,876 | 842,704 | -3% | -$10,198,844 | |||||
2025-07-17 | JNJ | Johnson & Johnson | Reed John C | EVP, Innovative Medicine, R, D | S - Sale | $163.55 | -19,137 | 10,658 | -64% | -$3,129,830 | ||||||
| DM | 2025-07-16 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Dir | S - Sale+OE | $353.19 | -29,101 | 1,116,584 | -3% | -$10,278,098 | |||||
2025-07-17 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | GC | S - Sale | $1.13 | -1,304 | 399,937 | 0% | -$1,470 | ||||||
2025-07-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | CFO | S - Sale | $1.12 | -11 | 474,462 | 0% | -$12 | ||||||
| D | 2025-07-17 | MRUS | Merus N.V. | Silverman Peter B. | COO, GC | S - Sale+OE | $60.00 | -25,000 | 0 | -100% | -$1,500,000 | |||||
2025-07-16 | PHAT | Phathom Pharmaceuticals, Inc. | Breedlove Robert Charles | Principal Accounting Officer | S - Sale | $8.36 | -1,692 | 53,500 | -3% | -$14,152 | ||||||
| D | 2025-07-17 | APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | CEO | S - Sale+OE | $20.21 | -19,725 | 1,871,027 | -1% | -$398,735 | |||||
2025-07-16 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $19.55 | -5,000 | 208,866 | -2% | -$97,750 | ||||||
2025-07-18 | CALC | Calcimedica, Inc. | Wilson Robert N | Dir | P - Purchase | $2.87 | +4,500 | 422,029 | +1% | +$12,915 | ||||||
2025-07-18 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $2.88 | +2,000 | 1,010,910 | 0% | +$5,760 | ||||||
2025-07-17 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $2.90 | +5,000 | 147,832 | +4% | +$14,495 | ||||||
2025-07-16 | MNKD | Mannkind Corp | Binder Steven B. | Dir | S - Sale | $3.94 | -75,367 | 830,508 | -8% | -$296,946 | ||||||
2025-07-16 | MNKD | Mannkind Corp | Thomson David | EVP Genl Counsel, Secretary | S - Sale | $3.94 | -7,466 | 841,719 | -1% | -$29,416 | ||||||
2025-07-15 | ETNB | 89Bio, Inc. | Le-Nguyen Quoc | See Remarks | S - Sale | $11.02 | -10,461 | 323,580 | -3% | -$115,280 | ||||||
2025-07-15 | PTCT | Ptc Therapeutics, Inc. | Gravier Pierre | CFO | S - Sale | $49.46 | -2,516 | 71,920 | -3% | -$124,441 | ||||||
| DM | 2025-07-15 | NAMS | Newamsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | $21.26 | -98,612 | 44,000 | -69% | -$2,096,655 | |||||
| DM | 2025-07-15 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $84.67 | -20,000 | 61,734 | -24% | -$1,693,496 | |||||
| D | 2025-07-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $82.27 | -27,000 | 249,062 | -10% | -$2,221,419 | |||||
| D | 2025-07-15 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $14.93 | -6,000 | 110,886 | -5% | -$89,567 | |||||
| D | 2025-07-14 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $5.01 | -6,500 | 0 | -100% | -$32,565 | |||||
| D | 2025-07-14 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale+OE | $40.00 | -8,904 | 11,486 | -44% | -$356,171 | |||||
| D | 2025-07-14 | MNPR | Monopar Therapeutics | Starr Christopher M | Dir | S - Sale+OE | $40.00 | -16,800 | 15,053 | -53% | -$672,020 | |||||
| D | 2025-07-14 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO | S - Sale+OE | $40.00 | -16,800 | 895,727 | -2% | -$672,020 | |||||
2025-07-14 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | SVP, COMM, MEDICAL AFFAIRS | S - Sale | $11.39 | -10,000 | 326,918 | -3% | -$113,870 | ||||||
| D | 2025-07-14 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $28.72 | -18,900 | 49,163 | -28% | -$542,808 | |||||
2025-07-14 | ANNX | Annexon, Inc. | Yednock Ted | EVP, CHIEF INNOVATION OFFICER | S - Sale | $2.58 | -1,116 | 105,084 | -1% | -$2,879 | ||||||
2025-07-14 | ANNX | Annexon, Inc. | Lew Jennifer | EVP, CFO | S - Sale | $2.58 | -1,117 | 121,616 | -1% | -$2,882 | ||||||
2025-07-14 | ANNX | Annexon, Inc. | Overdorf Michael | EVP, CHIEF BUSINESS OFFICER | S - Sale | $2.61 | -853 | 130,689 | -1% | -$2,226 | ||||||
2025-07-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $14.00 | -8,500 | 435,142 | -2% | -$118,962 | ||||||
| DM | 2025-07-14 | APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | CEO | S - Sale+OE | $20.19 | -139,365 | 1,881,755 | -7% | -$2,813,091 | |||||
2025-07-14 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $2.43 | +6,500 | 1,008,910 | +1% | +$15,810 | ||||||
2025-07-14 | CALC | Calcimedica, Inc. | Leheny A. Rachel | CEO, 10% | P - Purchase | $2.47 | +2,500 | 873,752 | 0% | +$6,175 | ||||||
2025-07-11 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale | $41.74 | -1,160 | 179,820 | -1% | -$48,416 | ||||||
| D | 2025-07-15 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $102.38 | -6,830 | 588,335 | -1% | -$699,220 | |||||
| M | 2025-07-11 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $99.80 | -1,681 | 66,394 | -2% | -$167,757 | |||||
2025-07-14 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $38.15 | -5,000 | 397,274 | -1% | -$190,750 | ||||||
2025-07-14 | DYN | Dyne Therapeutics, Inc. | Cox John | CEO, Pres | P - Purchase | $9.11 | +100,000 | 274,179 | +57% | +$911,000 | ||||||
2025-07-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $14.51 | -15,884 | 846,405 | -2% | -$230,431 | ||||||
2025-07-11 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | CFO, Secretary | S - Sale | $14.45 | -10,758 | 206,612 | -5% | -$155,454 | ||||||
| D | 2025-07-14 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $14.59 | -11,366 | 97,907 | -10% | -$165,879 | |||||
| D | 2025-07-14 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $14.28 | -7,836 | 592,477 | -1% | -$111,898 | |||||
| D | 2025-07-14 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $14.28 | -5,327 | 271,413 | -2% | -$76,070 | |||||
| D | 2025-07-14 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $14.28 | -4,797 | 223,231 | -2% | -$68,501 | |||||
2025-07-14 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale | $14.28 | -2,673 | 142,499 | -2% | -$38,170 | ||||||
| D | 2025-07-14 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $14.28 | -11,580 | 406,412 | -3% | -$165,362 | |||||
| D | 2025-07-14 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $14.28 | -20,252 | 2,626,822 | -1% | -$289,199 | |||||
| D | 2025-07-14 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $14.28 | -20,252 | 2,626,822 | -1% | -$289,199 | |||||
2025-07-14 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale | $14.28 | -1,193 | 187,168 | -1% | -$17,036 | ||||||
| D | 2025-07-14 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $14.28 | -2,576 | 193,634 | -1% | -$36,785 | |||||
| D | 2025-07-10 | AGIO | Agios Pharmaceuticals, Inc. | Scadden David | Dir | S - Sale+OE | $40.00 | -1,400 | 17,603 | -7% | -$56,000 | |||||
2025-07-11 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $3.14 | +10,000 | 943,334 | +1% | +$31,400 | ||||||
2025-07-10 | IRON | Disc Medicine, Inc. | Franchi Jean M. | CFO | S - Sale | $57.50 | -2,000 | 65,530 | -3% | -$115,000 | ||||||
| D | 2025-07-10 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $22.66 | -1,000 | 23,000 | -4% | -$22,655 | |||||
| D | 2025-07-10 | CORT | Corcept Therapeutics Inc | Swisher Daniel N Jr | Dir | S - Sale+OE | $71.08 | -2,200 | 0 | -100% | -$156,376 | |||||
| D | 2025-07-10 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $300.31 | -11,000 | 36,781 | -23% | -$3,303,394 | |||||
2025-07-10 | COGT | Cogent Biosciences, Inc. | Fairmount Funds Management LLC | Dir | P - Purchase | $9.00 | +2,777,777 | 9,003,418 | +45% | +$24,999,993 | ||||||
2025-07-14 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $64.88 | -400 | 78,945 | -1% | -$25,952 | ||||||
| DM | 2025-07-10 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale+OE | $15.05 | -28,750 | 115,468 | -20% | -$432,700 | |||||
2025-07-11 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.15 | +5,000 | 574,925 | +1% | +$15,750 | ||||||
2025-07-10 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale | $51.16 | -30,000 | 520,757 | -5% | -$1,534,895 | ||||||
2025-07-10 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $125.00 | -934 | 46,456 | -2% | -$116,750 | ||||||
| M | 2025-06-02 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $4.80 | +84 | 32,653 | 0% | +$404 | |||||
| M | 2025-06-02 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $4.80 | +168 | 5,699,428 | 0% | +$807 | |||||
| M | 2025-06-02 | CPIX | Cumberland Pharmaceuticals Inc | Jones James | Dir | P - Purchase | $4.80 | +168 | 43,336 | 0% | +$807 | |||||
| M | 2025-06-02 | CPIX | Cumberland Pharmaceuticals Inc | Krogulski Kenneth | Dir | P - Purchase | $4.83 | +935 | 286,633 | 0% | +$4,513 | |||||
2025-07-09 | TRDA | Entrada Therapeutics, Inc. | Parmar Kush | Dir, 10% | S - Sale | $7.50 | -27,000 | 4,256,379 | -1% | -$202,554 | ||||||
2025-07-09 | TRDA | Entrada Therapeutics, Inc. | 5Am Ventures V, L.P. | 10% | S - Sale | $7.50 | -27,000 | 4,256,379 | -1% | -$202,554 | ||||||
2025-07-09 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale | $253.38 | -27,802 | 53,867,649 | 0% | -$7,044,591 | ||||||
| D | 2025-07-09 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | $37.99 | -11,914 | 61,271 | -16% | -$452,601 | |||||
| D | 2025-07-09 | IRON | Disc Medicine, Inc. | Quisel John D | CEO | S - Sale+OE | $55.33 | -34,800 | 161,828 | -18% | -$1,925,525 | |||||
| D | 2025-07-09 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale+OE | $80.48 | -42,120 | 116,915 | -26% | -$3,389,756 | |||||
| D | 2025-07-09 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $77.78 | -7,969 | 8,509 | -48% | -$619,851 | |||||
| D | 2025-07-09 | RYTM | Rhythm Pharmaceuticals, Inc. | German Christopher Paul | Corporate Controller, CAO | S - Sale+OE | $80.75 | -3,817 | 922 | -81% | -$308,217 | |||||
| DM | 2025-07-09 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $80.31 | -7,645 | 60,956 | -11% | -$613,986 | |||||
| D | 2025-07-09 | RYTM | Rhythm Pharmaceuticals, Inc. | Cramer Pamela J. | CHRO | S - Sale+OE | $77.13 | -15,572 | 19,209 | -45% | -$1,201,062 | |||||
| DM | 2025-07-09 | MRUS | Merus N.V. | Silverman Peter B. | COO, GC | S - Sale+OE | $55.00 | -23,500 | 0 | -100% | -$1,292,500 | |||||
2025-07-09 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale | $15.69 | -32,979 | 369,595 | -8% | -$517,523 | ||||||
| M | 2025-07-08 | PBYI | Puma Biotechnology, Inc. | Nougues Maximo F | CFO | S - Sale | $3.53 | -9,522 | 204,229 | -4% | -$33,649 | |||||
| M | 2025-07-08 | PBYI | Puma Biotechnology, Inc. | Hunt Douglas M | See Remarks | S - Sale | $3.53 | -7,817 | 164,894 | -5% | -$27,624 | |||||
2025-07-09 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | Chief Development Officer | S - Sale | $15.69 | -30,250 | 127,939 | -19% | -$474,698 | ||||||
| M | 2025-07-08 | PBYI | Puma Biotechnology, Inc. | Auerbach Alan H | Pres, CEO, 10% | S - Sale | $3.53 | -47,172 | 7,180,901 | -1% | -$166,702 | |||||
2025-07-09 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $1.60 | +5,000 | 1,002,410 | +1% | +$8,024 | ||||||
| M | 2025-07-10 | OTLC | Oncotelic Therapeutics, Inc. | Trieu Vuong | COB, CEO, 10% | P - Purchase | $0.01 | +198,737 | 117,041,210 | 0% | +$994 | |||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | Silverstein Christine Berni | Dir | S - Sale | $5.86 | -13,093 | 120,479 | -10% | -$76,669 | ||||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $5.86 | -69,420 | 1,234,341 | -5% | -$406,503 | ||||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $5.86 | -25,411 | 479,168 | -5% | -$148,799 | ||||||
2025-07-08 | ABEO | Abeona Therapeutics Inc. | Wuchterl Donald A. | Dir | S - Sale | $5.82 | -5,176 | 145,436 | -3% | -$30,147 | ||||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | Charles Faith L. | Dir | S - Sale | $5.86 | -10,738 | 139,094 | -7% | -$62,879 | ||||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $5.86 | -17,428 | 360,817 | -5% | -$102,053 | ||||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Dir | S - Sale | $5.86 | -13,093 | 77,252 | -14% | -$76,669 | ||||||
2025-07-08 | ELTP | Elite Pharmaceuticals Inc /Nv/ | Plassche Douglas | EVP Operations | S - Sale | $0.58 | -200,000 | 2,300,000 | -8% | -$115,800 | ||||||
2025-07-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $19.79 | -6,667 | 296,642 | -2% | -$131,951 | ||||||
| D | 2025-07-07 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale+OE | $51.09 | -12,500 | 167,124 | -7% | -$638,661 | |||||
2025-07-07 | MURA | Mural Oncology Plc | Loew Caroline | CEO | S - Sale | $2.43 | -12,531 | 293,059 | -4% | -$30,475 | ||||||
| M | 2025-07-08 | ETST | Earth Science Tech, Inc. | Sanchez Yovan Arturo | Dir | P - Purchase | $0.18 | +33,044 | 1,700,000 | +2% | +$5,938 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |